<DOC>
	<DOCNO>NCT01075906</DOCNO>
	<brief_summary>Colchicine widely recognize safe effective treatment Familial Mediterranean Fever ( FMF ) child adult . Colchicine currently use treat FMF young patient inexact dose break crush adult-dose tablet . An age-appropriate sprinkle formulation allow accurate dose pediatric patient . The primary objective study evaluate compare steady-state pharmacokinetics multiple oral dos colchicine sprinkle capsule administer pediatric adult FMF patient . Secondary objective include evaluation safety tolerability regimen pediatric adult FMF patient measurement level acute phase reactant ( i.e , serum amyloid A [ SAA ] , erythrocyte sedimentation rate [ ESR ] , C-reactive protein [ CRP ] ) baseline dosing .</brief_summary>
	<brief_title>Pharmacokinetics Study Colchicine Familial Mediterranean Fever ( FMF ) Patients</brief_title>
	<detailed_description>FMF patient take colchicine ( colchicine-naïve patient ) enrol 1 week dose-titration period ( Days -7 -1 ) . Beginning Day -7 , pre-dose blood sample collect colchicine-naïve patient population determination pharmacodynamic marker . Patients administer low start dose colchicine ( determine principal investigator ) titrate study colchicine dose 0.6 mg ( 2 capsule ) child ≥2 &lt; 6 year old , 0.9 mg ( 3 capsule ) child ≥6 &lt; 12 , 1.2 mg ( 4 capsule ) child ≥12 &lt; 16 adult ≥16 &lt; 65 . On Day 2 , patient return clinic collection pre-dose blood sample follow administration study dose colchicine . On Days 3-7 , patient ( parent/guardian ) self-medicate study dose colchicine record time dose adverse event . On Days 8-14 , patient ( parent/guardian ) self-medicate study dose colchicine record time dose adverse event . On morning Day 15 , patient return clinic collection pre-dose blood sample follow administration study dose colchicine . Blood sample collect post-dose time sufficient adequately define pharmacokinetics colchicine metabolite . Safety tolerability dose regimen determine evaluation vital sign adverse event study upon completion study . All adverse event evaluate investigator report subject 's case report form .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Patients age 265 year confirm clinical diagnosis FMF , Nonpregnant , If childbearing potential , use effective contraceptive measure . Recent participation ( within 30 day ) research study , Pregnant lactating , History current infection human immunodeficiency virus ( HIV ) , hepatitis A , B C , Current recent use drugs/drug class combination thereof may affect absorption metabolism colchicine , Clinically relevant abnormal clinical laboratory screen , Current recent ( &lt; 6 month ) history severe , unstable uncontrolled neurological , cardiovascular , gastrointestinal , hematological , moderate severe hepatic and/or renal disease , evidence disease physical examination conduct screening .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>